Kusajili – Centralise les essais cliniques mondiaux

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with aspergillosis. PURPOSE: Randomized phase III trial to compare the effectiveness of voriconazole with amphotericin B in treating patients with aspergillosis.

• Pays Australia, Belgium, France, Germany, Hungary, Ireland, Israel, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

BUILD 3: Bosentan Use in Interstitial Lung Disease BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

• Pays Australia, Austria, Belgium, Canada, Croatia, Czech Republic, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Serbia, Spain, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Open-label Study With Bosentan in Interstitial Lung Disease This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.

• Pays Canada, France, Germany, Israel, Italy, Korea, Republic of, Netherlands, Sweden, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects The first study with rivaroxaban in pediatric subjects is a Phase I study, where the pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to confirm that the exposure is comparable to adults. This study is a single dose study with multiple PK/PD measurements in pediatric subjects at the end of their Venous Thromboembolism (VTE) treatment.

• Pays Australia, Austria, Canada, France, Germany, Ireland, Israel, Italy, Switzerland, United States,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis. Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available. The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF. It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.

• Pays Canada, France, Germany, Israel, Italy, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

• Pays Austria, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

• Pays Australia, Belgium, Canada, Czech Republic, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Spain, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.

• Pays France, Germany, Israel, Italy, Netherlands, Sweden, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Efficacy and Safety of Adalimumab in Patients With Active Uveitis A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.

• Pays Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland, Portugal, Spain, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

• Pays Canada, Egypt, France, Germany, Hungary, India, Israel, Japan, Singapore, Spain, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun